

Serial No.: 08/450,437
Group Art Unit No.: 1711

IN THE CLAIMS:

Please amend the claims, as follows:

20/11 15. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim 1.

28/22 16. (Amended) A method for the treatment and/or prophylaxis of convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of an NK₃ receptor antagonist.

23 22. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, pharmaceutically acceptable, and non-toxic amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim *17*.

42 25. (Amended) A method for the treatment and/or prophylaxis of pulmonary disorders [(asthma, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough)], skin disorders and itch [(for example, atopic dermatitis and cutaneous wheal and flare)], neurogenic inflammation and CNS disorders [(Parkinson's disease, movement disorders, anxiety)], convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders [(food intake inhibition)], allergic

Serial No.: 08/450,437
Group Art Unit No.: 1711

rhinitis, neurodegenerative disorders [(for example Alzheimer's disease)], psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, pharmaceutically acceptable, and non-toxic amount of a compound of formula (I), or a solvate or salt thereof, as defined in claim 23.⁴⁰

(Please add new claims 26-58, as follows:)

12-26. The method according to claim 15, wherein the pulmonary disorder is asthma.

13-27. The method according to claim 15¹¹, wherein the pulmonary disorder is chronic obstructive pulmonary disease.

14-28. The method according to claim 15¹¹, wherein the pulmonary disorder is airway hyperreactivity.

15-29. The method according to claim 15, wherein the pulmonary disorder is cough.

16-30. The method according to claim 15¹¹, wherein the skin disorder is atopic dermatitis.

17-31. The method according to claim 15¹¹, wherein the skin disorder is cutaneous wheal and flare.

18-32. The method according to claim 15¹¹, wherein the CNS disorder is Parkinson's disease.

19-33. The method according to claim 15¹¹, wherein the CNS disorder comprises movement disorders.

20-34. The method according to claim 15¹¹, wherein the CNS disorder is anxiety.

21-35. The method according to claim 15¹¹, wherein the eating disorder is food intake inhibition.

22-36. The method according to claim 15¹¹, wherein the neurodegenerative disorder is Alzheimer's disease.

29-37. The method according to claim 22²⁸, wherein the pulmonary disorder is asthma.

30-38. The method according to claim 22²⁸, wherein the pulmonary disorder is chronic obstructive pulmonary disease.

31-39. The method according to claim 22²⁸, wherein the pulmonary disorder is airway hyperreactivity.

32-40. The method according to claim 22²⁸, wherein the pulmonary disorder is cough.

33-41. The method according to claim 22²⁸, wherein the skin disorder is atopic dermatitis.

34-42. The method according to claim 22²⁸, wherein the skin disorder is cutaneous wheal and flare.

35-43. The method according to claim 22²⁸, wherein the CNS disorder is Parkinson's disease.

102